e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adaptimmune Therapeutics plc - American Depositary Shares
(NQ:
ADAP
)
0.1402
-0.0133 (-8.66%)
Streaming Delayed Price
Updated: 11:11 AM EDT, Oct 6, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adaptimmune Therapeutics plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Adaptimmune Therapeutics Earnings Preview
March 05, 2024
Via
Benzinga
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
February 21, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
Analyst Expectations for Adaptimmune Therapeutics's Future
August 10, 2023
Via
Benzinga
Recap: Adaptimmune Therapeutics Q1 Earnings
May 12, 2023
Via
Benzinga
Earnings Preview For Adaptimmune Therapeutics
May 11, 2023
Via
Benzinga
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
January 31, 2024
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for...
Via
Newsfile
12 Health Care Stocks Moving In Monday's After-Market Session
January 29, 2024
Via
Benzinga
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
January 04, 2024
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be...
Via
Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
December 15, 2023
Via
Benzinga
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
December 06, 2023
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better...
Via
Newsfile
Adaptimmune Receives Transfer of IND for Lete-cel Program
November 29, 2023
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma...
Via
Newsfile
Adaptimmune Reports Third Quarter Financial Results and Business Update
November 08, 2023
Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission...
Via
Newsfile
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
November 08, 2023
Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen...
Via
Newsfile
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
October 31, 2023
~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response...
Via
Newsfile
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
October 31, 2023
40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had...
Via
Newsfile
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
October 25, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in...
Via
Newsfile
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
October 23, 2023
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across...
Via
Newsfile
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
September 11, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces...
Via
Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
August 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 24, 2023
Via
Benzinga
Adaptimmune Reports Second Quarter Financial Results and Business Update
August 09, 2023
Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell...
Via
Newsfile
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
August 03, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader...
Via
Newsfile
Stocks That Hit 52-Week Lows On Friday
July 28, 2023
Friday's session saw 59 companies set new 52-week lows.
Via
Benzinga
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
June 01, 2023
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical...
Via
Newsfile
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
May 25, 2023
Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1...
Via
Newsfile
Stocks That Hit 52-Week Lows On Tuesday
June 06, 2023
On Tuesday, 69 stocks hit new 52-week lows.
Via
Benzinga
Earnings Scheduled For May 12, 2023
May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter.
Via
Benzinga
Adaptimmune Reports First Quarter Financial Results and Business Update
May 12, 2023
Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed...
Via
Newsfile
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Facebook
Twitter
YouTube